Refine
Has Fulltext
- yes (27)
Is part of the Bibliography
- yes (27)
Year of publication
Document Type
- Journal article (27)
Language
- English (27)
Keywords
- T cells (4)
- GvHD (2)
- Multiple myeloma (2)
- alloreactive T cells (2)
- cancer (2)
- immune cells (2)
- mouse models (2)
- regulatory T cells (2)
- Activation (1)
- Allogeneic stem cell transplantation (1)
- Alpha therapy (1)
- Aspergillus (1)
- Autoimmune diseases (1)
- B cells (1)
- BRAF mutation (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- CD11b+ myeloid cells (1)
- CNS cancer (1)
- CRISPR/Cas9 (1)
- Cancer treatment (1)
- Capicua transcriptional repressor (1)
- Drug resistance (1)
- Expression (1)
- Extramedullary disease (1)
- Factor receptor (1)
- Fak regulation (1)
- GVHD (1)
- Graft-versus-host disease (1)
- Graft-versus-leukemia (1)
- IRF4 (1)
- Immunology (1)
- Induced apoptosis (1)
- Infectious disease (1)
- Lichtheimia (1)
- Lymphomas (1)
- MPI (1)
- MPS (1)
- Mechanisms (1)
- Medizin (1)
- Migration (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Multiple (1)
- NF-Kappa-B (1)
- NFAT (1)
- NFATc1 (1)
- Parkinson's disease (1)
- Pathogenesis (1)
- Phase- (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Spleen (1)
- Stromal cells (1)
- Suppression (1)
- T-cell transfer (1)
- TNF (1)
- TNFR family costimulatory receptors (1)
- TNFR2 (1)
- TNFR2 agonists (1)
- TNFR2 antagonism (1)
- Tregs (regulatory T cells) (1)
- Trypanosoma (1)
- Tumor-necrosis-factor (1)
- VLA-1 (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- agonist (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- antigen-presenting cells (1)
- aspergillus fumigatus (1)
- autologous transplantation (1)
- biomarkers Myelomas (1)
- biophysics (1)
- bone imaging (1)
- bone marrow (1)
- bortezomib plus dxamethasone (1)
- brain tumor (1)
- calcofluor white staining (1)
- cancer microenvironment (1)
- cancer stem cells (1)
- cancer treatment (1)
- cell staining (1)
- cereblon expression (1)
- children (1)
- corticosteroids and cyclophosphamide (1)
- crosslinked coating (1)
- cytokines (1)
- cytotoxic T cells (1)
- elderly patients (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- fungal infection model (1)
- gRNA-only (1)
- gene regulation (1)
- graft vs. host disease (1)
- group 3 (1)
- homing (1)
- imaging agents (1)
- immune cell recruitment (1)
- immune control (1)
- immunotherapy (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- magnetic properties (1)
- megakaryocytes (1)
- mesenteric lymph node (1)
- metabolism (1)
- metastasis (1)
- microswimmer (1)
- monoclonal gammopathy (1)
- multiparameter flow-cytpmetry (1)
- multiple myeloma Lesions (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myeloma cells (1)
- naive T-cell gene editing (1)
- neuroimmunology (1)
- none (1)
- orthotopic xenograft (1)
- paediatric cancer (1)
- prediction (1)
- randomized phase-3 trial (1)
- serum retention (1)
- signal transduction (1)
- silkworm (1)
- sleeping sickness (1)
- spleen (1)
- stem-cell transplantation (1)
- structural biology (1)
- thalidomide maintenance (1)
- thrombopoiesis (1)
- transient regulatory T-cell targeting (1)
- transplantation (1)
- tsetse fly (1)
- tumour immunology (1)
- undetermined significance MGUS (1)
Institute
- Medizinische Klinik und Poliklinik II (25)
- Pathologisches Institut (7)
- Institut für Virologie und Immunbiologie (6)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (5)
- Kinderklinik und Poliklinik (5)
- Graduate School of Life Sciences (4)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Rudolf-Virchow-Zentrum (3)
- Neurochirurgische Klinik und Poliklinik (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 825575 (1)
In mammals, megakaryocytes (MKs) in the bone marrow (BM) produce blood platelets, required for hemostasis and thrombosis. MKs originate from hematopoietic stem cells and are thought to migrate from an endosteal niche towards the vascular sinusoids during their maturation. Through imaging of MKs in the intact BM, here we show that MKs can be found within the entire BM, without a bias towards bone-distant regions. By combining in vivo two-photon microscopy and in situ light-sheet fluorescence microscopy with computational simulations, we reveal surprisingly slow MK migration, limited intervascular space, and a vessel-biased MK pool. These data challenge the current thrombopoiesis model of MK migration and support a modified model, where MKs at sinusoids are replenished by sinusoidal precursors rather than cells from a distant periostic niche. As MKs do not need to migrate to reach the vessel, therapies to increase MK numbers might be sufficient to raise platelet counts.
Invasive fungal infections (IFIs) are difficult to diagnose and to treat and, despite several available antifungal drugs, cause high mortality rates. In the past decades, the incidence of IFIs has continuously increased. More recently, SARS-CoV-2-associated lethal IFIs have been reported worldwide in critically ill patients. Combating IFIs requires a more profound understanding of fungal pathogenicity to facilitate the development of novel antifungal strategies. Animal models are indispensable for studying fungal infections and to develop new antifungals. However, using mammalian animal models faces various hurdles including ethical issues and high costs, which makes large-scale infection experiments extremely challenging. To overcome these limitations, we optimized an invertebrate model and introduced a simple calcofluor white (CW) staining protocol to macroscopically and microscopically monitor disease progression in silkworms (Bombyx mori) infected with the human pathogenic filamentous fungi Aspergillus fumigatus and Lichtheimia corymbifera. This advanced silkworm A. fumigatus infection model could validate knockout mutants with either attenuated, strongly attenuated or unchanged virulence. Finally, CW staining allowed us to efficiently visualize antifungal treatment outcomes in infected silkworms. Conclusively, we here present a powerful animal model combined with a straightforward staining protocol to expedite large-scale in vivo research of fungal pathogenicity and to investigate novel antifungal candidates.
Combined MEK‐BRAF inhibition is a well‐established treatment strategy in BRAF‐mutated cancer, most prominently in malignant melanoma with durable responses being achieved through this targeted therapy. However, a subset of patients face primary unresponsiveness despite presence of the activating mutation at position V600E, and others acquire resistance under treatment. Underlying resistance mechanisms are largely unknown, and diagnostic tests to predict tumor response to BRAF‐MEK inhibitor treatment are unavailable.
Multiple myeloma represents the second most common hematologic malignancy, and point mutations in BRAF are detectable in about 10% of patients. Targeted inhibition has been successfully applied, with mixed responses observed in a substantial subset of patients mirroring the widespread spatial heterogeneity in this genomically complex disease. Central nervous system (CNS) involvement is an extremely rare, extramedullary form of multiple myeloma that can be diagnosed in less than 1% of patients. It is considered an ultimate high‐risk feature, associated with unfavorable cytogenetics, and, even with intense treatment applied, survival is short, reaching less than 12 months in most cases. Here we not only describe the first patient with an extramedullary CNS relapse responding to targeted dabrafenib and trametinib treatment, we furthermore provide evidence that a point mutation within the capicua transcriptional repressor (CIC) gene mediated the acquired resistance in this patient.
The highly motile and versatile protozoan pathogen Trypanosoma brucei undergoes a complex life cycle in the tsetse fly. Here we introduce the host insect as an expedient model environment for microswimmer research, as it allows examination of microbial motion within a diversified, secluded and yet microscopically tractable space. During their week-long journey through the different microenvironments of the fly´s interior organs, the incessantly swimming trypanosomes cross various barriers and confined surroundings, with concurrently occurring major changes of parasite cell architecture. Multicolour light sheet fluorescence microscopy provided information about tsetse tissue topology with unprecedented resolution and allowed the first 3D analysis of the infection process. High-speed fluorescence microscopy illuminated the versatile behaviour of trypanosome developmental stages, ranging from solitary motion and near-wall swimming to collective motility in synchronised swarms and in confinement. We correlate the microenvironments and trypanosome morphologies to high-speed motility data, which paves the way for cross-disciplinary microswimmer research in a naturally evolved environment.
Tumor necrosis factor (TNF) receptor-2 (TNFR2) has attracted considerable interest as a target for immunotherapy. Indeed, using oligomeric fusion proteins of single chain-encoded TNFR2-specific TNF mutants (scTNF80), expansion of regulatory T cells and therapeutic activity could be demonstrated in various autoinflammatory diseases, including graft-versus-host disease (GvHD), experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). With the aim to improve the in vivo availability of TNFR2-specific TNF fusion proteins, we used here the neonatal Fc receptor (FcRn)-interacting IgG1 molecule as an oligomerizing building block and generated a new TNFR2 agonist with improved serum retention and superior in vivo activity.
Methods
Single-chain encoded murine TNF80 trimers (sc(mu)TNF80) were fused to the C-terminus of an in mice irrelevant IgG1 molecule carrying the N297A mutation which avoids/minimizes interaction with Fcγ-receptors (FcγRs). The fusion protein obtained (irrIgG1(N297A)-sc(mu)TNF80), termed NewSTAR2 (New selective TNF-based agonist of TNF receptor 2), was analyzed with respect to activity, productivity, serum retention and in vitro and in vivo activity. STAR2 (TNC-sc(mu)TNF80 or selective TNF-based agonist of TNF receptor 2), a well-established highly active nonameric TNFR2-specific variant, served as benchmark. NewSTAR2 was assessed in various in vitro and in vivo systems.
Results
STAR2 (TNC-sc(mu)TNF80) and NewSTAR2 (irrIgG1(N297A)-sc(mu)TNF80) revealed comparable in vitro activity. The novel domain architecture of NewSTAR2 significantly improved serum retention compared to STAR2, which correlated with efficient binding to FcRn. A single injection of NewSTAR2 enhanced regulatory T cell (Treg) suppressive activity and increased Treg numbers by > 300% in vivo 5 days after treatment. Treg numbers remained as high as 200% for about 10 days. Furthermore, a single in vivo treatment with NewSTAR2 upregulated the adenosine-regulating ectoenzyme CD39 and other activation markers on Tregs. TNFR2-stimulated Tregs proved to be more suppressive than unstimulated Tregs, reducing conventional T cell (Tcon) proliferation and expression of activation markers in vitro. Finally, singular preemptive NewSTAR2 administration five days before allogeneic hematopoietic cell transplantation (allo-HCT) protected mice from acute GvHD.
Conclusions
NewSTAR2 represents a next generation ligand-based TNFR2 agonist, which is efficiently produced, exhibits improved pharmacokinetic properties and high serum retention with superior in vivo activity exerting powerful protective effects against acute GvHD.
Inflammation in the brain and gut is a critical component of several neurological diseases, such as Parkinson’s disease (PD). One trigger of the immune system in PD is aggregation of the pre-synaptic protein, α-synuclein (αSyn). Understanding the mechanism of propagation of αSyn aggregates is essential to developing disease-modifying therapeutics. Using a brain-first mouse model of PD, we demonstrate αSyn trafficking from the brain to the ileum of male mice. Immunohistochemistry revealed that the ileal αSyn aggregations are contained within CD11c+ cells. Using single-cell RNA sequencing, we demonstrate that ileal CD11c\(^+\) cells are microglia-like and the same subtype of cells is activated in the brain and ileum of PD mice. Moreover, by utilizing mice expressing the photo-convertible protein, Dendra2, we show that CD11c\(^+\) cells traffic from the brain to the ileum. Together these data provide a mechanism of αSyn trafficking between the brain and gut.
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.